Canada Continuous Glucose Monitoring Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Base Year Market Size (2026) | USD 348.33 Million |
| Market Size (2027) | USD 390.24 Million |
| Market Size (2032) | USD 688.66 Million |
| Growth Rate (2027 - 2032) | 12.03 % |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Canada Continuous Glucose Monitoring Market Analysis by Mordor Intelligence
The Canada Continuous Glucose Monitoring Market size is expected to grow from USD 348.33 million in 2026 to USD 390.24 million in 2027 and is forecast to reach USD 688.66 million by 2032 at 12.03% CAGR over 2027-2032.
According to Diabetes Canada, at the beginning of the COVID-19 pandemic, studies showed that diabetes was one of the major comorbidities associated with the development of severe COVID-19-related adverse outcomes and mortality. Adults living with diabetes who contracted COVID-19 were at higher risk of developing adult respiratory distress syndrome, pneumonia, excessive uncontrolled inflammation responses, and a hypercoagulable state.
Early reports placed the odds of in-hospital death from COVID-19 to be 2.85 times higher in adults living with diabetes compared to patients without diabetes. According to experts, inpatient use of diabetes technology in patients with proper institutional protocols was safe, and improved inpatient glycemic outcomes played a vital role in managing hypoglycemia and hyperglycemia in hospitalized patients.
CGM systems provide continuous visibility into glucose trends rather than isolated readings, enabling patients and healthcare professionals to identify patterns and respond to abnormal glucose levels. This capability strengthens the role of CGM in personalized diabetes management.
Furthermore, the current continuous glucose monitoring can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. The newest CGM (continuous glucose monitoring) models, the Abbott Freestyle Libre 3, and the Dexcom G7, overcame many technical barriers. Technological advances such as Eversense E3 CGMs have significantly improved the ability of providers and patients to manage diabetes, thereby enhancing the market prospects in the years to come.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Canada Continuous Glucose Monitoring Market Trends and Insights
Rising Diabetes Prevalence in Canada is anticipated to boost the market studied.
In the current year, according to Diabetes Canada, more than 5.7 million Canadians are living with diagnosed diabetes (type 1 or type 2 diabetes); however, 11.7 million Canadians are living with diabetes or prediabetes, a condition that, if left unmanaged, can develop into type 2 diabetes. Diabetes is also costing the healthcare system USD 30 billion per year to treat people with diabetes.
Monitoring blood glucose levels serves as a useful adjunct to other measures of glycemia, including A1C. It is the optimal way to confirm and appropriately treat hypoglycemia. It can provide feedback on the results of healthy behavior interventions and antihyperglycemic pharmacological treatments. It can increase one's empowerment and adherence to treatment. It can also provide information to both the person with diabetes and their diabetes healthcare team to facilitate longer-term treatment modifications and titrations as well as shorter-term treatment decisions, such as insulin dosing for people with type 1 or type 2 diabetes. In situations where A1C does not accurately reflect glycemia, monitoring blood glucose is necessary to adequately monitor glycemia.
International and national diabetes-care initiatives increasingly emphasize improved access to monitoring technologies and stronger integration of diabetes management into primary healthcare. Such policy priorities can support broader adoption of CGM and other monitoring solutions.
The Canadian Diabetes Strategy (CDS) is a national partnership that includes the provinces and territories, many national health organizations and groups, and aboriginal communities across the country. The purpose of the CDS is to establish effective diabetes prevention and control strategies for Canada through its various partners to ensure that resources are deployed accordingly.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and increasing awareness through government initiatives.
The Sensors Segment is Expected to Hold the Highest Share Over the Forecast Period
Continuous glucose monitoring devices are automated glucose monitoring systems that consist of a small device that can be worn on the body and held on by an adhesive patch. The sensor part of the device has a cannula that is inserted into the top layer of skin and uses samples of interstitial fluid to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Sensors are the most important part of continuous glucose monitoring devices.
Innovation in sensor technology is focused on improving accuracy, wear duration, comfort, affordability, and ease of use. Emerging optical and other non-traditional sensing approaches could further expand the range of CGM solutions available to patients and improve long-term adoption.
Competitive Landscape
The Canada continuous glucose monitoring market is consolidated, with few significant players. There have been constant innovations driven by manufacturers such as Abbott, Dexcom, Medtronic, etc., while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
Canada Continuous Glucose Monitoring Industry Leaders
-
Ascensia
-
Abbott
-
Dexcom
-
GlySens
-
Medtronic
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- October 2023: Dexcom launched its next-generation G7 continuous glucose monitor (CGM) in Canada for people with all types of diabetes aged two and older, including those who are pregnant, in the country.
- March 2023: Dexcom announced that all people with type 1 and type 2 diabetes in Manitoba, Canada, meet eligibility criteria for its G6 CGM. As of the company’s announcement, Manitoba is the only province in Canada that does not require an application for coverage preapproval.
Canada Continuous Glucose Monitoring Market Report Scope
Achieving optimum glycaemic results can be very difficult without frequent monitoring of blood glucose levels. A continuous glucose monitor tracks blood sugar levels 24 hours a day. It collects readings automatically every five to fifteen minutes and detects trends and patterns to provide a complete picture of diabetes. The Canada continuous glucose monitoring market is segmented into components (sensors and durables). The report offers the value (in USD) and volume (in units) for the above segments.
| Sensors |
| Durables |
| Component | Sensors |
| Durables |
Key Questions Answered in the Report
How big is the Canada Continuous Glucose Monitoring Market?
The Canada Continuous Glucose Monitoring Market size is expected to reach USD 390.24 million in 2027 and grow at a CAGR of 12.03% to reach USD 688.66 million by 2032.
What is the current Canada Continuous Glucose Monitoring Market size?
In 2026, the Canada Continuous Glucose Monitoring Market size is expected to reach USD 348.33 million.
Who are the key players in Canada Continuous Glucose Monitoring Market?
Ascensia, Abbott, Dexcom, GlySens and Medtronic are the major companies operating in the Canada Continuous Glucose Monitoring Market.
What years does this Canada Continuous Glucose Monitoring Market cover, and what was the market size in 2026?
In 2026, the Canada Continuous Glucose Monitoring Market size was estimated at USD 348.33 million. The report covers the Canada Continuous Glucose Monitoring Market historical market size for years: 2021, 2022, 2023, 2024 and 2025. The report also forecasts the Canada Continuous Glucose Monitoring Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.